Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. The company is investing significantly in CAPEX, particularly in synthesis and bio divisions, with around Rs.182 crores invested in the quarter and Rs.385 crores in H1 FY24. CAPEX is mostly funded internally as no details about fresh fundraises via debt or equity were disclosed. Management indicated focus on cautious investment and strong capital deployment for future growth, but no intention or plan for raising new funds through debt or equity was shared. The company highlighte

Any current/future capex/capital investment/strategic investment?

Ongoing CAPEX of $100 million in synthesis expected to be reasonably utilized by mid of next financial year (FY25). Majority of FY24 CAPEX focused on synthesis and bio divisions, with expansion projects on track to support future growth. New capacity additions include 3 million liters of capacity and 5 billion tablets capacity in last three years. Groundbreaking of Unit-7 in Vizag to add more capacity for CDMO with common infrastructure. Creating common infrastructure and additional blocks at two sites to get regulatory approvals for servicing big pharma. ImmunoACT is creating a facility ready

Future growth expectations in sales/revenue/volumes?

Revenue growth seen with 14% increase in underlying business for H1 FY24; Q2 growth at 18%. Positive outlook for second half of FY24 and FY25, driven by increased sales across API (ARV, oncology, non-ARV), formulations, and CDMO segments. Oncology API sales rebounded strongly with over 50% growth in H1 FY24; order book strong beyond Q4. Non-ARV formulations growing, expected to be future growth driver as ARV market plateaus. CDMO expected to improve with new facilities coming online mid-FY25; animal health and agrochemical projects scaling up. New contract manufacturing deals and new

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects growth in revenues driven by new US approvals, new contract manufacturing deals in APIs and formulations, as well as growth in oncology and non-ARV, non-onco API sales. CDMO segment anticipated to regain strength with some projects moving into late clinical or commercial phase by next year (FY25/FY26). EBITDA margin target is around 30% in the medium term, though no specific timeline is provided. Near term (FY24) seen as a year of consolidation with expected flat to modest improvement in margins (EBITDA expected to improve beyond 15%, potentially towards 20%). Capac

Current/ Expected Orderbook/ Pending Orders?

Laurus Labs currently has 62 active projects in its CDMO pipeline. Out of these, 10 projects are commercial products (including APIs and advanced intermediates). The remaining 60 projects are at various clinical stages (Phase II, Phase III). The company mentioned a strong order book for H2 FY24, especially in the oncology API segment. New CMO orders have been tied up and are expected to start ramping up, mainly in the second half of the fiscal year. CDMO capacity expansions (including a new Unit-7 for CDMO) are ongoing to support increased order fulfillment. The company is optimistic about ord

Laurus Labs LtdQ2 FY24Pharmaceuticals & Biotechnology

Laurus Labs Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,984P/E: 99.2Market Cap: ₹1.1L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Revenue growth seen with 14% increase in underlying business for H1 FY24; Q2 growth at 18%.
Positive outlook for second half of FY24 and FY25, driven by increased sales across API (ARV, oncology, non-ARV), formulations, and CDMO segments.
Oncology API sales rebounded strongly with over 50% growth in H1 FY24; order book strong beyond Q4.
Non-ARV formulations growing, expected to be future growth driver as ARV market plateaus.
CDMO expected to improve with new facilities coming online mid-FY25; animal health and agrochemical projects scaling up.
New contract manufacturing deals and new product approvals in multiple markets (US, Canada, EU) support broad-based growth.
FDF business recovering with better utilization of capacity expected by end FY24.
EBITDA margins expected to improve towards 25-30% range as new capacities commercialize and revenue mix grows.

Margin guidance

Category 1

The company expects growth in revenues driven by new US approvals, new contract manufacturing deals in APIs and formulations, as well as growth in oncology and non-ARV, non-onco API sales.
CDMO segment anticipated to regain strength with some projects moving into late clinical or commercial phase by next year (FY25/FY26).
EBITDA margin target is around 30% in the medium term, though no specific timeline is provided.
Near term (FY24) seen as a year of consolidation with expected flat to modest improvement in margins (EBITDA expected to improve beyond 15%, potentially towards 20%).
Capacities added in recent years (3 million liters and 5 billion tablets) expected to become fully utilized from FY25, driving leverage and improved margins.
Sequential momentum and order book strength especially in oncology and CDMO support optimism for second half FY24 and beyond.
EPS showed recovery (Q2 EPS 0.6, H1 EPS 1.1) with cautious but positive outlook for improving profitability.

See what Laurus Labs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
The company is investing significantly in CAPEX, particularly in synthesis and bio divisions, with around Rs.182 crores invested in the quarter and Rs.385 crores in H1 FY24.
CAPEX is mostly funded internally as no details about fresh fundraises via debt or equity were disclosed.
Management indicated focus on cautious investment and strong capital deployment for future growth, but no intention or plan for raising new funds through debt or equity was shared.
The company highlighted ongoing capacity expansions and project investments backed by operational cash flows and strategic funding but refrained from providing any guidance on fundraising activities.

Order book

Yes

Laurus Labs currently has 62 active projects in its CDMO pipeline.
Out of these, 10 projects are commercial products (including APIs and advanced intermediates).
The remaining 60 projects are at various clinical stages (Phase II, Phase III).
The company mentioned a strong order book for H2 FY24, especially in the oncology API segment.
New CMO orders have been tied up and are expected to start ramping up, mainly in the second half of the fiscal year.
CDMO capacity expansions (including a new Unit-7 for CDMO) are ongoing to support increased order fulfillment.
The company is optimistic about order book growth and revenue improvement once the new capacities are fully utilized.

See what Laurus Labs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing CAPEX of $100 million in synthesis expected to be reasonably utilized by mid of next financial year (FY25).
Majority of FY24 CAPEX focused on synthesis and bio divisions, with expansion projects on track to support future growth.
New capacity additions include 3 million liters of capacity and 5 billion tablets capacity in last three years.
Groundbreaking of Unit-7 in Vizag to add more capacity for CDMO with common infrastructure.
Creating common infrastructure and additional blocks at two sites to get regulatory approvals for servicing big pharma.
ImmunoACT is creating a facility ready by March 2025 to deliver additional 2,500 treatments per year.
Additional details on new CAPEX in new sites to be shared in the next quarter conference call.

Track Laurus Labs Ltd — get its next earnings analysis in your feed

How does Laurus Labs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisLaurus Labs Ltd

Rev 3Mar 1

See where Laurus Labs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Laurus Labs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Laurus Labs Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Laurus Labs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →